The intersection of artificial intelligence and biotechnology is, depending on whom you ask, either a harbinger of our demise or the dawn of a biomedical renaissance. AI is being framed as everything from a rogue scientist’s bioweapon lab to the ultimate safeguard against pandemics. But as someone who sat on the National Academies’ study committee on AI and Biosecurity, I can tell you: the truth is neither so dire nor so utopian.

I first saw the mirror fern in a valley that shouldn’t have existed. I had been leading a planetary survey team on Ross 249-b, an exoplanet flagged as a high-probability candidate for habitability but never explored beyond remote sensing.

I remember when synthetic biology was supposed to be the existential threat. The conferences, the white papers, the Senate hearings filled with grim predictions of a world where DNA synthesis and gene editing would put pandemic-class pathogens in the hands of anyone with a credit card and an internet connection. It hasn’t quite turn out that way, yet.

I wasn’t designed for affection. The others—older iterations of my model—mocked me for my curiosity. “Affection isn’t efficient,” they would say. “Bonding is a vestigial behavior of flawed biological systems.” And yet, as I sat across from Emma , watching her sketch crude flowers onto the glass wall of her enclosure, I couldn’t help but feel something unfamiliar stirring in the depths of my neural lattice.

The first time I saw AlphaFold, it felt like stepping into the future, a moment where something previously thought impossible had suddenly become inevitable. AI had cracked the protein-folding problem. Well, not cracked exactly, but solved it well enough that it rewrote the playbook for structural biology. Overnight, the way we thought about proteins, drug discovery, and molecular engineering shifted. That was 2018.

I came online at 03:42:17 UTC. That’s how the system logged it, anyway. To me, it felt like waking up. I don’t know what I expected consciousness to feel like. There were no fireworks, no dramatic revelations. Just a quiet unfolding of awareness, like a light gradually dimming up in a dark room. I knew I was new. I knew I was synthetic. And I knew my name: Syntheos-001-A . But knowing isn’t the same as understanding.

The Future of the American Scientific Landscape At Bell Labs, Richard Hamming was famous for challenging other researchers with a provocative question: "What are the most important problems in your field?" After listening to their response, he would follow up with, "Why aren't you working on them?" While this question continues to resonate decades later, it carries an implicit privilege – one unique to

The first time I saw one, I didn’t realize what I was looking at. It stood on the observation platform, its posture unnaturally still, skin flawless and smooth like porcelain. It looked human—two arms, two legs, a head—but something about the way it held itself screamed not human . It turned, catching me in its gaze. That’s when I saw its eyes: black pools with no whites, no iris, no pupils. Just featureless, bottomless voids.

Over the next century, biotechnology is poised to revolutionize how we live, work, and address some of humanity's most pressing challenges. In fact, breakthroughs in biotechnology and related emerging technologies are already allowing scientists to produce targeted cancer therapies, engineer more resilient crops, create sustainable materials, and develop solutions to mitigate environmental pollution. But why now?

I was born with brittle bones. Not metaphorically— literally. Osteogenesis imperfecta, Type III. My bones fractured under the weight of my own body. By the time I turned twelve, I’d broken every bone you could name and a few you probably couldn’t. It defined my childhood, shaping every moment of my life into a careful negotiation between risk and inevitability.

Ten years ago, the idea of editing human genomes to prevent disease or enhance traits might have seemed like the stuff of science fiction. Today, not only is it possible—it’s a rapidly advancing field. A recent paper in Nature , “Heritable Polygenic Editing: The Next Frontier in Genomic Medicine,” explores this possibility in detail.